Bruker AXS Announces SMART BREEZE(TM), an Affordable and Exceptionally Easy-to-Use X-Ray Crystallography System for Automated Molecular 3D Structure Analysis.MADISON, Wis. -- Bruker AXS Inc. today announces the launch of SMART BREEZE(TM), a compact and affordable X-ray crystallography system, which features Bruker AXS' latest addition to its award-winning X-ray detectors, the air-cooled SMART BREEZE 4K CCD CCD in full charge-coupled device Semiconductor device in which the individual semiconductor components are connected so that the electrical charge at the output of one device provides the input to the next device. detector, as well as a compact goniometer goniometer /go·ni·om·e·ter/ (go?ne-om´e-ter) 1. an instrument for measuring angles. 2. a plank that can be tilted at one end to any height, used in testing for labyrinthine disease. and X-ray generator. The SMART BREEZE system features the ground-breaking new AutoStructure(TM) software for fully automatic 3D structure determination of organic and coordination molecules from X-ray data. The SMART BREEZE's advanced CCD technology allows it to be air-cooled for low maintenance while offering a very high level of data quality, superior to most conventional water-cooled detectors. This novel system with its intuitive and automated software for structure determination is ideal for synthetic chemistry research groups, as well as for chemistry teaching facilities. Dr. Michael Ruf, Director of Chemical Crystallography Software at Bruker AXS, stated: "X-ray crystallography has never been easier. After having defined the high-performance end of the chemical crystallography market for many years with cutting-edge hardware and software technology, we are now very excited to be able to offer a lower-cost system with truly automated, robust structure determination software. The innovative SMART BREEZE system finally opens the door to crystallographic crys·tal·log·ra·phy n. The science of crystal structure and phenomena. crys tal·log structure determination for non-experts. We expect that easy and fast access to unambiguous structural confirmation of new compounds will have a rather significant impact on the world of synthetic chemistry." About Bruker Biosciences (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. , headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading worldwide developer and provider of advanced X-ray systems which provide solutions for molecular and elemental analysis by X-ray crystallography, X-ray diffraction and X-ray fluorescence. Its integrated systems, which have particular application in the life-science and materials-science fields, provide customers with high throughput capabilities to determine the 3D structure of specific molecules, such as proteins, and to characterize and determine the composition of materials. Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . Please visit www.bruker-axs.com Cautionary Statement Any statements contained in this press release with respect to Bruker AXS or Bruker BioSciences or their businesses that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||

tal·log
Printer friendly
Cite/link
Email
Feedback
Reader Opinion